JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases
-
By
-
Bingrun Li
-
Xiaoting Song
-
Cunhao Shan
-
Junchen He
-
Zihan Wang
-
Katarina Stevanovic
-
Torsten Zuberbier
-
Zuotao Zhao
-
Litao Zhang
-
June 18, 2026
-
Clinical Scorecard: A Comprehensive Functional Framework for Inflammatory Skin Disorders Linked to the JAK-STAT Signaling Pathway
At a Glance
| Category | Detail |
|---|
| Condition | Inflammatory Skin Disorders |
| Key Mechanisms | JAK-STAT signaling pathway |
| Target Population | Patients with atopic dermatitis, psoriasis, alopecia areata, vitiligo, and other inflammatory skin diseases |
| Care Setting | Clinical settings for dermatological treatment |
Key Highlights
- JAK inhibitors (JAKi) show substantial efficacy in treating inflammatory skin diseases.
- Abrocitinib and upadacitinib are approved for moderate-to-severe atopic dermatitis.
- Baricitinib is approved for severe alopecia areata.
- Traditional classification of inflammatory skin diseases is inadequate for guiding targeted therapy.
- A functional refinement framework integrating JAK-dependent cytokine modules is proposed.
Guideline-Based Recommendations
Diagnosis
- Utilize the JAK-STAT pathway for a unified understanding of inflammatory skin diseases.
Management
- Consider small molecule JAK inhibitors for treatment of inflammatory skin disorders.
Monitoring & Follow-up
- Assess treatment responses based on JAK-STAT pathway involvement.
Risks
- Potential immunogenicity and efficacy attenuation over extended treatment periods with biologics.
Patient & Prescribing Data
Individuals with moderate-to-severe atopic dermatitis and severe alopecia areata.
JAK inhibitors may offer broader effects than biologics targeting single cytokines.
Clinical Best Practices
- Integrate JAK-STAT pathway analysis into clinical diagnosis and treatment planning.
- Utilize a mechanistic understanding of cytokine interactions for precision medicine.
Related Resources & Content
